NEW YORK (GenomeWeb) – Health plan management firm MagnaCare has signed a deal to provide GenTox's pharmacogenomic testing services to members of its provider network, the companies announced today.
"This initiative promises to provide doctors with the valuable information they need to achieve more efficient dosing of critical medications and provides access to information for the most effective choices based upon each patient’s unique genetic makeup obtained through the testing," MagnaCare CEO Joseph Berardo said in a statement.
Under the arrangement, MagnaCare will begin offering GenTox's services to patients receiving anti-coagulants with the goal of mitigating adverse drug reactions and hospital readmissions due to medication mismanagement.
"Choosing the wrong anti-coagulation medication has been proven to cause heart attacks in one out of every 23 patients," GenTox CEO Matthew Bennett added. "GenTox is honored to partner with MagnaCare on this important initiative at a time when many hospitals and physicians have begun to adopt these life-saving measures."
Additional details of the deal were not disclosed.